Literature DB >> 10587144

Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.

R T Heelan1, V W Rusch, C B Begg, D M Panicek, J F Caravelli, C Eisen.   

Abstract

OBJECTIVE: This article compares the accuracy of CT with that of MR imaging in staging of malignant pleural mesothelioma. SUBJECTS AND METHODS: Ninety-five patients were enrolled in a prospective staging protocol based on the International Mesothelioma Interest Group staging system. Sixty-five patients underwent CT and MR imaging and a surgical procedure (excluding percutaneous needle biopsy) to stage and resect the tumor. Receiver operating characteristic analyses were performed. CT and MR scans were interpreted independently by observers who were unaware of the results of the other imaging study; these imaging findings were compared with the results of surgery and pathologic examination.
RESULTS: The areas under the receiver operating characteristic curves for eight of 10 features revealed by imaging showed no statistically significant differences between CT and MR imaging. However, MR imaging was superior to CT in revealing invasion of the diaphragm (A(z) = .55 for CT versus .82 for MR imaging) and in revealing invasion of endothoracic fascia or solitary resectable foci of chest wall invasion (A(z) = .46 for CT; A(z) = .69 for MR imaging). Several anatomic regions could not be evaluated because positive findings at surgery were rare.
CONCLUSION: CT and MR imaging are of nearly equivalent diagnostic accuracy in staging malignant pleural mesothelioma. MR imaging is superior to CT in revealing solitary foci of chest wall invasion and endothoracic fascia involvement and in showing diaphragmatic muscle invasion; however, this advantage does not affect surgical treatment. For cost reasons, CT should be considered the standard diagnostic study before therapy.

Entities:  

Mesh:

Year:  1999        PMID: 10587144     DOI: 10.2214/ajr.172.4.10587144

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  41 in total

Review 1.  Malignant pleural mesothelioma: an update on diagnosis and treatment options.

Authors:  Sanjana Kondola; David Manners; Anna K Nowak
Journal:  Ther Adv Respir Dis       Date:  2016-02-12       Impact factor: 4.031

2.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

3.  Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.

Authors:  Valerie W Rusch
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 4.  Diagnosis, staging, and surgical treatment of malignant pleural mesothelioma.

Authors:  Michael Kent; David Rice; Raja Flores
Journal:  Curr Treat Options Oncol       Date:  2008-08-29

Review 5.  Radical multimodality therapy for malignant pleural mesothelioma.

Authors:  Omar Abdel-Rahman; Zeinab Elsayed; Hadeer Mohamed; Mostafa Eltobgy
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

Review 6.  Overview of treatment related complications in malignant pleural mesothelioma.

Authors:  David J Murphy; Ritu R Gill
Journal:  Ann Transl Med       Date:  2017-06

Review 7.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

8.  Tract metastasis from previously unknown malignant pleural mesothelioma: a case report.

Authors:  Tommaso Bartalena; Maria Francesca Rinaldi; Nicola Sverzellati; Vincenzo Allegri; Stefano Fanti
Journal:  Cases J       Date:  2009-06-29

9.  Update on pleural diseases--2007.

Authors:  Ayman Bishay; Suhail Raoof; Adebayo Esan; Arthur Sung; Siraj Wali; Leonard Y Lee; Liziamma George; Anthony Saleh; Michael Baumann
Journal:  Ann Thorac Med       Date:  2007-07       Impact factor: 2.219

Review 10.  Radiation exposure from chest CT: issues and strategies.

Authors:  Mannudeep K Kalra; Michael M Maher; Stefania Rizzo; David Kanarek; Jo-Anne O Shepard; Jo-Anne O Shephard
Journal:  J Korean Med Sci       Date:  2004-04       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.